683 Capital Management’s Orchestra BioMed OBIO Stock Holding History

683 Capital Management’s Portfolio OBIO Stock Details OBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$786K	Sell	185,000 -19,076	-9%	-$81.2K	0.04%	151
2025 Q4	$847K	Buy	+204,076	New	+$823K	0.04%	158
2022 Q3	–	Sell	-10,000	Closed	-$100K	–	247
2022 Q2	$100K	Hold	10,000	–	–	0.01%	189
2022 Q1	$99K	Hold	10,000	–	–	0.01%	289
2021 Q4	$101K	Hold	10,000	–	–	﹤0.01%	303
2021 Q3	$99K	Hold	10,000	–	–	﹤0.01%	193
2021 Q2	$102K	Hold	10,000	–	–	﹤0.01%	189
2021 Q1	$112K	Hold	10,000	–	–	0.01%	156
2020 Q4	$128K	Hold	10,000	–	–	0.01%	203
2020 Q3	$110K	Buy	+10,000	New	+$112K	0.01%	132

Other funds holding OBIO

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

683 Capital Management's OBIO Position: Q1 2026 in Review

683 Capital Management reduced its Orchestra BioMed (OBIO) stake by 9.3% in Q1 2026, selling an estimated $81.2K and leaving 185,000 shares worth $786K. The position accounts for 0.04% of the portfolio, ranked #151.

683 Capital Management first reported a position in OBIO in Q3 2020 and has held it in 10 quarters since. The position peaked at $847K in Q4 2025. 65 funds tracked by Wall St. Rank hold OBIO as of Q1 2026.

683 Capital Management held 185,000 shares of Orchestra BioMed worth $786K as of Q1 2026.
683 Capital Management sold 19,076 Orchestra BioMed shares in Q1 2026, an estimated $81.2K.
Orchestra BioMed made up 0.04% of 683 Capital Management's portfolio in Q1 2026, its #151 holding.
683 Capital Management first reported a position in Orchestra BioMed in Q3 2020 and has held it in 10 quarters since.
683 Capital Management's Orchestra BioMed position peaked at $847K in Q4 2025.
65 funds tracked by Wall St. Rank held Orchestra BioMed as of Q1 2026.

Based on 683 Capital Management's 13F filing for Q1 2026, filed 15 May 2026.